JNX Stock Overview
Acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Therma Bright Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.025 |
| 52 Week High | CA$0.054 |
| 52 Week Low | CA$0.0005 |
| Beta | 2.67 |
| 1 Month Change | 34.21% |
| 3 Month Change | 37.84% |
| 1 Year Change | n/a |
| 3 Year Change | -89.61% |
| 5 Year Change | 920.00% |
| Change since IPO | -85.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| JNX | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 34.2% | 3.6% | 1.5% |
| 1Y | n/a | -3.2% | 12.6% |
Return vs Industry: Insufficient data to determine how JNX performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how JNX performed against the German Market.
Price Volatility
| JNX volatility | |
|---|---|
| JNX Average Weekly Movement | 49.2% |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: JNX's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: JNX's weekly volatility has decreased from 74% to 49% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Rob Fia | www.thermabright.com |
Therma Bright Inc. acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. The company’s products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It also offers Inretio, a medical device for ischemic stroke treatment; Digital Cough Test (DCT), an app that uses artificial intelligence to detect multiple respiratory diseases; and inhaled statin therapy for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome in hospitalized patients.
Therma Bright Inc. Fundamentals Summary
| JNX fundamental statistics | |
|---|---|
| Market cap | €13.50m |
| Earnings (TTM) | -€1.81m |
| Revenue (TTM) | €2.97k |
4,548x
P/S Ratio-7.5x
P/E RatioIs JNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JNX income statement (TTM) | |
|---|---|
| Revenue | CA$4.47k |
| Cost of Revenue | CA$574.00 |
| Gross Profit | CA$3.90k |
| Other Expenses | CA$2.73m |
| Earnings | -CA$2.73m |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.006 |
| Gross Margin | 87.16% |
| Net Profit Margin | -60,996.02% |
| Debt/Equity Ratio | 2.6% |
How did JNX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/27 04:39 |
| End of Day Share Price | 2025/01/24 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Therma Bright Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|